SCHEMBL16999824

SCHEMBL16999824

c1ccc(-c2cc(-c3ccccc3)nc(-n3c4ccccc4c4cc5c(cc43)c3ccc4oc6ccccc6c4c3n5-c3ccccc3)n2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ LMNA P02545 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SIRT2 Q8IXJ6 1/20 0.31
▸ SIRT1 Q96EB6 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ BRCA1 P38398 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16999647 0.97 SMN1; SMN2 (0.34) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192537 0.96 KDM4E (0.38) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL16999689 0.94 KDM4E (0.35) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192618 0.94 L3MBTL1 (0.36) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192320 0.93 KDM4E (0.37) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL16999677 0.92 L3MBTL1 (0.35) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192503 0.92 L3MBTL1 (0.36) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192735 0.91 KDM4E (0.34) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192336 0.91 SMN1; SMN2 (0.34) SMN1; SMN2LMNAKDM4EATML3MBTL1
SCHEMBL22192322 0.91 SMN1; SMN2 (0.34) SMN1; SMN2LMNAKDM4EATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703762-B2 Compound, material for organic electroluminescence device, organic electroluminescence device and electronic apparatus IDEMITSU KOSAN CO., LTD. (JP) 2020-07-07 — — US disclosed
EP-2907815-A2 Condensed cyclic compound and organic light-emitting device including the same Samsung Electronics Co., Ltd (KR) 2015-08-19 — — EP disclosed
US-20150228909-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG SDI CO., LTD. (KR) 2015-08-13 — — US disclosed
US-20150228909-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG SDI CO., LTD. (KR) 2015-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150228909-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CCNE2, CRY2 SMN1; SMN2 3341/4885LMNA 2072/4885KDM4E 2145/4885
US-10703762-B2 Compound, material for organic electroluminescence device, organic electroluminescence device and electronic apparatus PIEZO1, OR10J3, EPCAM SMN1; SMN2 3814/4885LMNA 2806/4885KDM4E 3529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback